25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Key Takeaways The Federal Trade Commission (FTC), with the support of the Antitrust Division of the ...
Read More >
In Penn-America Insurance Company v. Bay State Gas Company, 96 Mass. App. Ct. 757 (2019), the Appeal...
Read More >
Paul Singer’s Elliott Management hedge fund revealed a $3.2 billion stake in AT&T and, along with i...
Read More >
Consistent with trends in recent years, in 2019 Delaware corporation law largely was shaped by post-...
Read More >
Continuing its shift toward more employer-friendly workplace decisions, the National Labor Relations...
Read More >
At a news conference on April 20, Governor Wolf announced he is extending his stay-at-home order unt...
Read More >